©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2016; 22(28): 6444-6455
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6444
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6444
Management of psoriasis patients with hepatitis B or hepatitis C virus infection
Claudio Bonifati, Viviana Lora, Dario Graceffa, Center for the Study and Treatment of Psoriasis San Gallicano Dermatologic Institute, IRCCS, 00144 Rome, Italy
Lorenzo Nosotti, Gastrointestinal and Liver Department, National Institute for Health, Migration and Poverty, 00153 Rome, Italy
Author contributions: Bonifati C performed research and wrote the paper; Lora V, Graceffa D and Nosotti L contributed critical revision of the manuscript.
Conflict-of-interest statement: No conflict of interest.
Correspondence to: Claudio Bonifati, MD, Center for the Study and Treatment of Psoriasis San Gallicano Dermatologic Institute, IRCCS, ViaElioChianesi 53, 00144 Rome, Italy. psoriasi@ifo.gov.it
Telephone: +39-6-52665140
Received: March 23, 2016
Peer-review started: March 23, 2016
First decision: May 12, 2016
Revised: May 25, 2016
Accepted: June 15, 2016
Article in press: June 15, 2016
Published online: July 28, 2016
Processing time: 121 Days and 11.9 Hours
Peer-review started: March 23, 2016
First decision: May 12, 2016
Revised: May 25, 2016
Accepted: June 15, 2016
Article in press: June 15, 2016
Published online: July 28, 2016
Processing time: 121 Days and 11.9 Hours
Core Tip
Core tip: At present, no guidelines give clear indications regarding the management of psoriasis patients with concomitant hepatitis B or hepatitis C virus infection who need a systemic treatment. On the basis of the available literature data, this paper provides an overview in this field from a practical point of view. A particular emphasis is given, with regard to the use of biological drugs, in the aforementioned patients.